Cardiotoxicity associated with the use of trastuzumab in breast cancer patients

被引：24

作者：

Perik, Patrick J. ^{[1
]}

de Korte, Maarten Alexander ^{[1
]}

van Veldhuisen, Dirk J. ^{[1
]}

Gietema, Jourik A. ^{[1
]}

Sleijfer, Dirk T. ^{[1
]}

de Vries, Elisabeth G. E. ^{[1
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol & Cardiol, NL-9700 RB Groningen, Netherlands

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2007年 / 7卷 / 12期

关键词：

breast cancer; cardiotoxicity; HER2; trastuzumab;

D O I：

10.1586/14737140.7.12.1763

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The monoclonal antibody against HER2, trastuzumab (Herceptin (R)), has become an important player in the treatment of patients with HER2-positive breast cancer. Both in the metastatic and adjuvant setting, the addition of trastuzumab to other systemic treatments has led to a striking increase in tumor response and survival. The downside with the use of this agent, however, is its inherent cardiotoxicity, which is particularly common when anthracyclines are used concurrently. This review will focus on all aspects of the cardiac side-effects of trastuzumab, ranging from epidemiology and pathophysiology to cardiac monitoring, and treatment and prevention.

引用

页码：1763 / 1771

页数：9

共 63 条

[1] Safety profile of Herceptin (R) as a single agent and in combination with chemotherapy
Baselga, J
[J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S324 - S324
[2] Behr TM, 2001, NEW ENGL J MED, V345, P995
[3] Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy
Cardinale, D
Sandri, MT
Colombo, A
Colombo, N
Boeri, M
Lamantia, G
Civelli, M
Peccatori, F
Martinelli, G
Fiorentini, C
Cipolla, CM
[J]. CIRCULATION, 2004, 109 (22) : 2749 - 2754
[4] Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition
Cardinale, Daniela
Colombo, Alessandro
Sandri, Maria T.
Lamantia, Giuseppina
Colombo, Nicola
Civelli, Maurizio
Martinelli, Giovanni
Veglia, Fabrizio
Fiorentini, Cesare
Cipolla, Carlo M.
[J]. CIRCULATION, 2006, 114 (23) : 2474 - 2481
[5] Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial
Chia, Stephen
Clemons, Mark
Martin, Lee-Ann
Rodgers, Angela
Gelmon, Karen
Pond, Gregory R.
Panasci, Lawrence
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2773 - 2778
[6] Docus on research: Herceptin and the heart - A molecular modifier of cardiac failure
Chien, KR
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) : 789 - 790
[7] ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, SA
Zhao, YY
Fan, L
Gu, YS
Minamisawa, S
Liu, Y
Peterson, KL
Chen, J
Kahn, R
Condorelli, G
Ross, J
Chien, KR
Lee, KF
[J]. NATURE MEDICINE, 2002, 8 (05) : 459 - 465
[8] 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure:: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity
de Korte, M. A.
de Vries, E. G. E.
Lub-de Hooge, M. N.
Jager, P. L.
Gietema, J. A.
van der Graaf, W. T. A.
Sluiter, W. J.
van Veldhuisen, D. J.
Suter, T. M.
Sleiffer, D. T.
Perik, P. J.
[J]. EUROPEAN JOURNAL OF CANCER, 2007, 43 (14) : 2046 - 2051
[9] MYOCYTE CELL-DAMAGE AFTER ADMINISTRATION OF DOXORUBICIN OR MITOXANTRONE IN BREAST-CANCER PATIENTS ASSESSED BY IN-111 ANTIMYOSIN MONOCLONAL-ANTIBODY STUDIES
ESTORCH, M
CARRIO, I
MARTINEZDUNCKER, D
BERNA, L
TORRES, G
ALONSO, C
OJEDA, B
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) : 1264 - 1268
[10] The anthracycline-trastuzumab interaction: Up-regulated binding may provide vital mechanistic insight
Ewer, Michael S.
[J]. EUROPEAN JOURNAL OF CANCER, 2007, 43 (14) : 2024 - 2025

← 1 2 3 4 5 6 7 →